KRN5500 Demonstrated Significant Decrease In The Intensity Of Neuropathic Pain In Patients With Cancer
by Zangani • 11 October 2011 • Pain News
DARA BioSciences, Inc. (NASDAQ:DARA) announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer…